Takara Bio Inc. (TYO:4974)
Japan
· Delayed Price · Currency is JPY 831.00
+9.00 (1.09%)
Apr 28, 2025, 3:30 PM JST
Takara Bio Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Revenue | 43,053 | 43,505 | 78,142 | 67,699 | 46,086 | 34,565 | Upgrade
|
| Revenue Growth (YoY) | -9.69% | -44.33% | 15.43% | 46.90% | 33.33% | -3.56% | Upgrade
|
| Cost of Revenue | 17,817 | 16,597 | 33,377 | 18,488 | 14,214 | 13,459 | Upgrade
|
| Gross Profit | 25,236 | 26,908 | 44,765 | 49,211 | 31,872 | 21,106 | Upgrade
|
| Selling, General & Admin | 16,526 | 15,615 | 15,570 | 14,180 | 12,357 | 10,952 | Upgrade
|
| Research & Development | 7,323 | 8,324 | 8,575 | 6,109 | 5,545 | 3,869 | Upgrade
|
| Operating Expenses | 24,124 | 23,905 | 24,224 | 20,309 | 17,919 | 14,830 | Upgrade
|
| Operating Income | 1,112 | 3,003 | 20,541 | 28,902 | 13,953 | 6,276 | Upgrade
|
| Interest Expense | -20 | -23 | -24 | -23 | -24 | -7 | Upgrade
|
| Interest & Investment Income | 275 | 186 | 142 | 122 | 113 | 141 | Upgrade
|
| Currency Exchange Gain (Loss) | -52 | 97 | -120 | -706 | 2 | -160 | Upgrade
|
| Other Non Operating Income (Expenses) | 248 | 140 | 142 | 163 | 115 | 95 | Upgrade
|
| EBT Excluding Unusual Items | 1,563 | 3,403 | 20,681 | 28,458 | 14,159 | 6,345 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | -2 | Upgrade
|
| Gain (Loss) on Sale of Assets | -354 | -344 | -97 | -168 | -98 | -31 | Upgrade
|
| Asset Writedown | -240 | -207 | - | -5,227 | -517 | -880 | Upgrade
|
| Other Unusual Items | -1 | - | 639 | 4,468 | 8 | -1 | Upgrade
|
| Pretax Income | 968 | 2,852 | 21,223 | 27,531 | 13,552 | 5,431 | Upgrade
|
| Income Tax Expense | 982 | 1,343 | 5,176 | 7,624 | 3,971 | 1,601 | Upgrade
|
| Earnings From Continuing Operations | -14 | 1,509 | 16,047 | 19,907 | 9,581 | 3,830 | Upgrade
|
| Minority Interest in Earnings | -38 | -29 | -35 | -58 | -34 | -11 | Upgrade
|
| Net Income | -52 | 1,480 | 16,012 | 19,849 | 9,547 | 3,819 | Upgrade
|
| Net Income to Common | -52 | 1,480 | 16,012 | 19,849 | 9,547 | 3,819 | Upgrade
|
| Net Income Growth | - | -90.76% | -19.33% | 107.91% | 149.99% | 4.43% | Upgrade
|
| Shares Outstanding (Basic) | 120 | 120 | 120 | 120 | 120 | 120 | Upgrade
|
| Shares Outstanding (Diluted) | 120 | 120 | 120 | 120 | 120 | 120 | Upgrade
|
| EPS (Basic) | -0.43 | 12.29 | 132.97 | 164.84 | 79.28 | 31.72 | Upgrade
|
| EPS (Diluted) | -0.43 | 12.29 | 132.97 | 164.84 | 79.28 | 31.72 | Upgrade
|
| EPS Growth | - | -90.76% | -19.33% | 107.91% | 149.99% | 4.43% | Upgrade
|
| Free Cash Flow | -4,100 | -11,067 | 31,150 | -5,418 | 5,256 | 2,356 | Upgrade
|
| Free Cash Flow Per Share | -34.05 | -91.91 | 258.69 | -44.99 | 43.65 | 19.57 | Upgrade
|
| Dividend Per Share | 17.000 | 17.000 | 42.000 | 33.000 | 16.000 | 8.000 | Upgrade
|
| Dividend Growth | -59.52% | -59.52% | 27.27% | 106.25% | 100.00% | 14.29% | Upgrade
|
| Gross Margin | 58.62% | 61.85% | 57.29% | 72.69% | 69.16% | 61.06% | Upgrade
|
| Operating Margin | 2.58% | 6.90% | 26.29% | 42.69% | 30.28% | 18.16% | Upgrade
|
| Profit Margin | -0.12% | 3.40% | 20.49% | 29.32% | 20.72% | 11.05% | Upgrade
|
| Free Cash Flow Margin | -9.52% | -25.44% | 39.86% | -8.00% | 11.40% | 6.82% | Upgrade
|
| EBITDA | 5,705 | 8,024 | 25,276 | 33,051 | 17,739 | 9,806 | Upgrade
|
| EBITDA Margin | 13.25% | 18.44% | 32.35% | 48.82% | 38.49% | 28.37% | Upgrade
|
| D&A For EBITDA | 4,593 | 5,021 | 4,735 | 4,149 | 3,786 | 3,530 | Upgrade
|
| EBIT | 1,112 | 3,003 | 20,541 | 28,902 | 13,953 | 6,276 | Upgrade
|
| EBIT Margin | 2.58% | 6.90% | 26.29% | 42.69% | 30.28% | 18.16% | Upgrade
|
| Effective Tax Rate | 101.45% | 47.09% | 24.39% | 27.69% | 29.30% | 29.48% | Upgrade
|
Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.